Trial Profile
A Phase I, First-in-human, Dose-escalation Study to Evaluate the Safety and Immunologic Response After Administration of HS-130 in Combination With HS-110 (Viagenpumatucel-L) in Patients With Solid Tumors Refractory to Standard Care
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs HS 130 (Primary) ; Viagenpumatucel-L (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors NightHawk Biosciences; Scorpius Holdings
- 06 Feb 2024 According to a NightHawk Biosciences media release, the NightHawk Biosciences has changed its name to Scorpius Holdings.
- 26 Aug 2022 Status changed from active, no longer recruiting to completed.
- 02 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Feb 2022.